Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PharmaTher Holdings Ltd ( (TSE:PHRM) ) has shared an announcement.
PharmaTher has filed a U.S. provisional patent application for stabilized peptide compositions designed for microneedle and transdermal delivery, aiming to protect peptides from degradation during manufacturing, drying, storage and use. The patent supports its PharmaPatch product strategy by enabling more practical dried peptide dosage forms and complements the PatchPrint manufacturing platform to create an integrated microneedle patch offering.
The filing covers formulation techniques using stabilizing components, layered microneedle designs that concentrate peptides in the tip region, and low-moisture packaging approaches to extend shelf life and preserve biological activity. PharmaTher expects this intellectual property to strengthen its competitive position, support in-house product development and lifecycle extensions, and open strategic partnership opportunities across multiple peptide categories and broader microneedle patch applications.
Spark’s Take on PHRM Stock
According to Spark, TipRanks’ AI Analyst, PHRM is a Neutral.
The score is primarily pressured by weak financial fundamentals (pre-revenue operations, ongoing losses, negative cash flow, and eroding equity) despite improving burn rate and zero reported debt. Technicals also weigh on the score as the stock remains in a broader downtrend. Valuation is limited by negative earnings and no dividend support.
To see Spark’s full report on PHRM stock, click here.
More about PharmaTher Holdings Ltd
PharmaTher Holdings Ltd. is a specialty pharmaceutical company focused on developing microneedle patch technologies for transdermal drug delivery. Its core platforms, PharmaPatch and PatchPrint, target patient-friendly delivery of peptides and other therapeutics, with potential applications ranging from small-molecule drugs and biologics to vaccines in clinical, hospital and remote settings.
YTD Price Performance: -38.10%
Average Trading Volume: 67,342
Technical Sentiment Signal: Sell
Current Market Cap: C$5.92M
Find detailed analytics on PHRM stock on TipRanks’ Stock Analysis page.